Table 1 Clinical, laboratory and cardio-pulmonary features of patients with idiopathic inflammatory myopathies
Variable | Median (min–max) |
|---|---|
Disease activity and damage | |
 Manual muscle test 8 (MMT8) | 144 (45–150) |
 Visual analogue scale of physician’s disease activity | 5 (0–10) |
 Visual analogue scale of patient’s disease activity | 5 (0–10) |
 Cutaneous dermatomyositis disease area and severity index (CDASI) acute | 4 (0–76) |
 Cutaneous dermatomyositis disease area and severity index (CDASI) chronic | 2 (0–21) |
 Visual analogue scale of constitutional disease activity | 0 (0–10) |
 Visual analogue scale of cutaneous disease activity | 0 (0–10) |
 Visual analogue scale of pulmonary disease activity | 0 (0–10) |
 Visual analogue scale of cardiovascular disease activity | 0 (0–10) |
 Visual analogue scale of other disease activity | 0 (0–10) |
 Visual analogue scale of extramuscular disease activity | 3 (0–10) |
 Visual analogue scale of muscular disease activity | 0 (0–10) |
 Visual analogue scale of global disease activity | 5 (0–10) |
 Total myositis disease activity assessment visual analogue scales (MYOACT) | 1.4 (0–7.5) |
 Total myositis intention to treat activity index (MITAX) | 0.85 (0–5.71) |
 Visual analogue scale of muscular damage | 0 (0–10) |
 Visual analogue scale of skeletal damage | 0 (0–9) |
 Visual analogue scale of cutaneous damage | 1 (0–10) |
 Visual analogue scale of gastrointestinal damage | 0 (0–10) |
 Visual analogue scale of pulmonary damage | 0 (0–8) |
 Visual analogue scale of cardiovascular damage | 0 (0–10) |
 Visual analogue scale of vascular damage | 0 (0–5) |
 Visual analogue scale of endocrine damage | 0 (0–10) |
 Visual analogue scale of ocular damage | 0 (0–10) |
 Visual analogue scale of infection damage | 0 (0–10) |
 Visual analogue scale of malignancy damage | 0 (0–5) |
 Visual analogue scale of other damage | 0 (0–10) |
 Visual analogue scale of global damage | 5 (0–10) |
 Damage extension | 0.04 (0–0.52) |
 Damage severity | 0.045 (0–0.5) |
 Extended damage | 0 (0–10) |
 Health assessment questionnaire (HAQ) | 0 (0–3) |
Treatment | |
 Prednisone dose (mg/day) | 15 (2–100) |
 Methotrexate dose (mg/week) | 20 (2.5–30) |
 Azathioprine dose (mg/day) | 75 (50–175) |
 Mycophenolate mofetil dose (g/day) | 1.5 (0.5–2.5) |
 Anti-malarial dose (mg/day) | 200 (150–400) |
Laboratory and cardio-pulmonary features | |
 Creatine phosphokinase (U/L) | 170 (10–13,325) |
 Aldolase (U/L) | 8.7 (6.2–131) |
 Alanine aminotransferase (U/L) | 31 (5–435) |
 Aspartate aminotransferase (U/L) | 30 (10–1441) |
 Lactate dehydrogenase (U/L) | 226 (45–1243) |
 C-reactive protein (mg/dL) | 0.26 (0.01–13.3) |
 Erythrocyte sedimentation rate (mm/Hr) | 8 (1–56) |
 Percentage of predicted forced vital capacity | 81 (45–108) |
 Pulmonary artery systolic pressure (mmHg) | 32 (20–62) |
 Percentage of left ventricle ejection fraction | 61 (37–76) |
 Tricuspid annular plane systolic excursion (TAPSE) | 20 (11–26) |